TELA Bio to Participate in Upcoming JMP Securities Life Sciences Conference
Get Alerts TELA Hot Sheet
Join SI Premium – FREE
MALVERN, Pa., June 14, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Company will participate in the JMP Securities Life Sciences Conference.
TELA Bio's management is scheduled to present at the JMP Securities Life Sciences Conference on Wednesday, June 16, 2021 at 11:30 AM EDT. Interested parties can access the live and archived webcast at ir.telabio.com.
About TELA Bio, Inc.
TELA Bio Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The Company is committed to providing patients with advanced, economically effective biologic material repair solutions to minimize long-term exposure to permanent synthetic materials and improve clinical outcomes. TELA Bio's OviTex® and OviTex PRS Reinforced Tissue Matrix products are purposefully designed to address the shortcomings of existing reinforcement materials in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. For more information, visit www.telabio.com.
Investor ContactGreg Chodaczek347-620-7010 [email protected]
Source: TELA Bio, Inc.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- New Jimmy Stewart Movie to Take Center Stage at AFA’s Air, Space & Cyber Conference
- Awager and BetMGM Bring Real Casino Slot Machines Online Through New Partnership
- Money Secrets, Financial Pressure and Delayed Milestones Are Reshaping Americans’ Relationships, TD Bank U.S. Survey Finds
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share